Mascoma Wealth Management LLC Buys 139 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mascoma Wealth Management LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 997 shares of the biopharmaceutical company’s stock after purchasing an additional 139 shares during the period. Mascoma Wealth Management LLC’s holdings in Gilead Sciences were worth $92,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Swedbank AB grew its holdings in Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at $102,000. Catalytic Wealth RIA LLC bought a new position in Gilead Sciences in the 3rd quarter worth $201,000. Venturi Wealth Management LLC lifted its position in Gilead Sciences by 60.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,493 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 565 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV lifted its position in Gilead Sciences by 49.9% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 8,447 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 2,813 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 311,285 shares of company stock valued at $31,284,910 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.4 %

Shares of NASDAQ:GILD opened at $113.99 on Thursday. The company’s fifty day moving average is $100.99 and its 200-day moving average is $92.33. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a market capitalization of $141.96 billion, a PE ratio of 308.08, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.77%. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Mizuho raised their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.